Quoin Q3 2026 net loss widens to ~$4.9M as QRX003 interim Phase 2/3 data meet primary endpoint

Quoin Pharmaceuticals, Ltd.

Q3 2026 net loss ~$4.9M vs ~$3.9M a year earlier; nine-month net loss ~$15.2M vs ~$11.5M; cash, equivalents and marketable securities ~$33.2M at Sept 30, 2026.
Interim Phase 2/3 CL-QRX003-004 data: 4 of 6 patients (66.7%) hit the IGA primary endpoint (p=0.0087 vs alpha 0.0215); key secondary p=0.0070; no treatment-related SAEs.
Aug 28 private placement with healthcare-focused institutions for up to ~$50.0M: ~$30.8M upfront plus up to ~$19.2M from ordinary warrant exercises.
FDA cleared the first-ever IND for QRX003 in Peeling Skin Syndrome (July 9), then granted RPD (Sept 8) and Fast Track (Sept 22); EMA added Orphan Drug status Oct 14.
All 20 Netherton Syndrome patients expected enrolled by end-2026 with topline in Q2 2027; first company-sponsored PSS study to start before year end.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.